Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Jeffrey V. Leyton"'
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 19, Iss , Pp 99-119 (2020)
The next breakthrough for protein therapeutics is effective intracellular delivery and accumulation within target cells. Nuclear localization signal (NLS)-tagged therapeutics have been hindered by the lack of efficient nuclear localization due to end
Externí odkaz:
https://doaj.org/article/600849ef0c184a67a2bd45823a6dde3c
Autor:
Michel Paquette, Serge Phoenix, Christine Lawson, Brigitte Guérin, Roger Lecomte, Lee-Hwa Tai, Éric E. Turcotte, Jeffrey V. Leyton
Publikováno v:
EJNMMI Research, Vol 10, Iss 1, Pp 1-13 (2020)
Abstract Background Nuclear medicine is on the constant search of precision radiopharmaceutical approaches to improve patient management. Although discordant expression of the estrogen receptor (ER) and the human epidermal growth factor receptor 2 (H
Externí odkaz:
https://doaj.org/article/13caea711fa04b23b55a868fec294dd5
Publikováno v:
Pharmaceuticals, Vol 14, Iss 7, p 674 (2021)
Biologically-based therapies increasingly rely on the endocytic cycle of internalization and exocytosis of target receptors for cancer therapies. However, receptor trafficking pathways (endosomal sorting (recycling, lysosome localization) and lateral
Externí odkaz:
https://doaj.org/article/8354b71c12c34d6fb3582d301dd6978e
Autor:
Brent A. Williams, Xing-Hua Wang, Jeffrey V. Leyton, Sonam Maghera, Bishoy Deif, Raymond M. Reilly, Mark D. Minden, Armand Keating
Publikováno v:
Haematologica, Vol 103, Iss 10 (2018)
Patients with acute myeloid leukemia (AML) often relapse after initial therapy because of persistence of leukemic stem cells that frequently express the IL-3 receptor alpha chain CD123. Natural killer (NK) cell-based therapeutic strategies for AML sh
Externí odkaz:
https://doaj.org/article/700f42d2215746699b30f75b4eb1cc92
Autor:
Olga Bednova, Jeffrey V. Leyton
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 19, p 7268 (2020)
The fact that there are now five immune checkpoint inhibitor (ICI) monoclonal antibodies approved since 2016 that target programmed cell death protein 1 or programmed death ligand-1 for the treatment of metastatic and refractory bladder cancer is an
Externí odkaz:
https://doaj.org/article/5a86240c633e4dbba88dddb35c6f6ddf
Autor:
Jeffrey V. Leyton
Publikováno v:
Antibodies, Vol 9, Iss 3, p 32 (2020)
Therapeutic anti-HER2 antibodies and antibody–drug conjugates (ADCs) have undoubtedly benefitted patients. Nonetheless, patients ultimately relapse—some sooner than others. Currently approved anti-HER2 drugs are expensive and their cost-effective
Externí odkaz:
https://doaj.org/article/cbba0f9969054b868c5db4a08687e5e3
Autor:
Michel Paquette, Luis-Guillermo Vilera-Perez, Simon Beaudoin, Nadia Ekindi-Ndongo, Pierre-Luc Boudreaut, Marc-Andre Bonin, Marie-Claude Battista, M'hamed Bentourkia, Angel F. Lopez, Roger Lecomte, Eric Marsault, Brigitte Guérin, Robert Sabbagh, Jeffrey V. Leyton
Publikováno v:
OncoImmunology, Vol 6, Iss 10 (2017)
Despite the high interest and concern due to an increasing incidence and death rate, patients who develop muscle invasive bladder cancer (MIBC) have few options available. However, the past decade has produced many candidate bladder tumor-specific ma
Externí odkaz:
https://doaj.org/article/39ceb8d0e9154c49a04dea5569cdba7a
Autor:
Jeffrey V. Leyton, Catherine Gao, Brent Williams, Armand Keating, Mark Minden, Raymond M. Reilly
Publikováno v:
Leukemia Research Reports, Vol 4, Iss 2, Pp 55-59 (2015)
Radioimmunotherapy (RIT) with anti-CD123 monoclonal antibody CSL360 modified with nuclear translocation sequence (NLS) peptides and labeled with the Auger electron-emitter, 111In (111In-NLS-CSL360) was studied in the prevalent NOD/SCID mouse AML engr
Externí odkaz:
https://doaj.org/article/7f4c964030a64f52a0fab85b34af5329
Autor:
Brent A. Williams, Arjun Law, Judit Hunyadkurti, Stephanie Desilets, Jeffrey V. Leyton, Armand Keating
Publikováno v:
Journal of Clinical Medicine, Vol 8, Iss 8, p 1261 (2019)
In recent decades, therapy for acute myeloid leukemia (AML) has remained relatively unchanged, with chemotherapy regimens primarily consisting of an induction regimen based on a daunorubicin and cytarabine backbone, followed by consolidation chemothe
Externí odkaz:
https://doaj.org/article/1f42a75037054404b9775c34b9568bcf
Autor:
Jeffrey V. Leyton, Tove Olafsen, Eric J.M. Lepin, Scott Hahm, Humphrey Fonge, Robert E. Reiter, Anna M. Wu
Publikováno v:
Molecular Imaging, Vol 12 (2013)
The humanized antibody (hu1G8) has been shown to localize to prostate stem cell antigen (PSCA) and image PSCA-positive xenografts. We previously constructed hu1G8 anti-PSCA antibody fragments and tested them for tumor targeting and the ability to ima
Externí odkaz:
https://doaj.org/article/e945b35041854179866b504881244c95